- Home
- VEL vs FTRE Comparison
VEL vs FTRE Comparison
Compare VEL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VEL | FTRE |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 829.3M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VEL | FTRE |
|---|---|---|
| Price | $19.43 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $22.00 | $14.06 |
| AVG Volume (30 Days) | 80.6K | ★ 913.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.98 | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $6.01 | N/A |
| Revenue Next Year | $19.02 | $3.09 |
| P/E Ratio | $7.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $16.12 | $3.97 |
| 52 Week High | $21.40 | $18.67 |
Technical Indicators
Market Signals| Indicator | VEL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 46.21 |
| Support Level | $19.37 | $9.56 |
| Resistance Level | $21.12 | $10.47 |
| Average True Range (ATR) | 0.50 | 0.63 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 68.25 | 39.04 |
Price Performance
Historical ComparisonAbout VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. Company operates in a large fragmented market with substantial demand for financing and limited supply of institutional financing alternative The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.